Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600415 | 0.83 | MEN1 (0.37) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3608154 | 0.83 | MEN1 (0.37) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3610113 | 0.83 | MEN1 (0.43) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3611539 | 0.82 | HDAC1 (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8248429 | 0.72 | MEN1 (0.55) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3610003 | 0.68 | GSTO1 (0.53) | MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL5592733 | 0.66 | ALDH1A1 (0.48) | SMN1; SMN2MEN1KMT2APOLBTDP1 | |
| SCHEMBL28277053 | 0.66 | TRPM8 (0.59) | SMN1; SMN2TRPM8POLBTDP1 | |
| SCHEMBL5438790 | 0.66 | TRPM8 (0.58) | TRPM8POLBTDP1 | |
| SCHEMBL3602399 | 0.65 | GSTO1 (0.50) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | NPC1 139/4885RAB9A 601/4885SMN1; SMN2 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.